4 completed, 1 no longer available. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow APT-1011: new trials by email Literature Review of APT-1011 trials Research Report on APT-1011
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 218 | 2022-12-29 | 2025-08-13 |
| Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial APT-1011, Placebo oral tablet - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 6 | 2021-09-30 | 2023-09-21 |
| Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 143 | 2020-01-30 | 2023-06-12 |
| Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) APT-1011, Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | Adare Pharmaceuticals, Inc. | 106 | 2017-06-22 | 2023-04-26 |
| Expanded Access Protocol for Patients With Eosinophilic Esophagitis APT-1011 3 mg HS - Eosinophilic Esophagitis | No longer available | Ellodi Pharmaceuticals, LP | 2025-10-03 |
Eosinophilic Esophagitis (5) · Esophageal Diseases (5) · Esophagitis (5) · Gastrointestinal Diseases (5) · Eosinophilia (4) · Gastroenteritis (4) · Hematologic Diseases (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Leukocyte Disorders (4) · Digestive System Diseases (3) · Deglutition Disorders (1)
Ellodi Pharmaceuticals, LP (4) · Adare Pharmaceuticals, Inc. (1)
United States (5) · Australia (2) · Canada (2) · Spain (2) · Belgium (1) · Germany (1) · Switzerland (1)
Evan Dellon, MD, MPH (2) · Mirna Chehade, MD, MPH (1) · Peter C Richardson (1)
2016 (1)